BioSpace News Archive

Yumanity Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease.

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, reported financial results for the three and nine months ended September 30, 2021 and provided a general business update.

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in-person at the 12th Annual Jefferies London Healthcare Conference on November 17, 2021, at 1:00pm GMT.

Diffusion Pharmaceuticals Inc., a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced financial results for the third quarter of 2021 and provided a business update.

Autolus Therapeutics plc (Nasdaq: AUTL), today announced the publication of an article in Nature Scientific Reports describing a controllable CAR T cell system (TetCAR), designed to reversibly dampen the activity of the programmed T cells by the administration of the licensed and widely available antibiotics tetracycline and minocycline.

Pluristem Therapeutics Inc., a leading biotechnology company, announced that it has received approval for an additional grant from the Israel Innovation Authority to support research based on its cutting-edge PLX platform.

PolyPid Ltd., a phase 3 biopharmaceutical company focusing on developing targeted, locally administered, and prolonged-release therapeutics to improve surgical outcomes, provided a corporate update and reported financial results for the three and nine months ended September 30, 2021.

Prelude Corporation (PreludeDx™), announced today that the American Medical Association (AMA) has issued a new, dedicated Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) code for DCISionRT®, the only test available to predict personalized recurrence risk and radiation therapy benefit for patients with ductal carcinoma in situ (DCIS).

Evofem Biosciences, Inc., announced that it has submitted the registration for its hormone-free contraceptive vaginal gel to the Mexican Regulatory Agency COFEPRIS.

TheraCell Inc., a leading allograft solution company, today announced that it was selected as a recipient of the 2021 Spine Technology Award, presented by Orthopedics This Week at the North American Spine Society (NASS) meeting in Boston last month.